Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab ... Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old ...

The corporation performed well in all regions: revenue increased by 14% in the US, 33% in Japan, and 39% in Europe ... from the current price of $138.76. Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals ... the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent for the treatment of chronic ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader market's ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Dupixent is the first new targeted therapy for CSU in a decade and is already approved in several countries, including Japan and Brazil ... Scientific Officer at Regeneron, and a principal ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for ...